Table 6.
Duration of the COVID-19-associated symptoms of the patients, Bangladesh, 2020.
| Symptoms | Group | 1–4 days | 5–10 days | 11–14 days | >14 days |
|---|---|---|---|---|---|
| Fever | Male | 241 (85.2%) | 34 (12.0%) | 3 (1.1%) | 5 (1.8%) |
| Female | 99 (79.8%) | 23 (18.5%) | 0 (0.0%) | 2 (1.6%) | |
| Total | 340 (83.5%) | 57 (14.0%) | 3 (0.7%) | 7 (1.7%) | |
| Exhaustion | Male | 17 (6.6%) | 23 (8.9%) | 125 (48.6%) | 92 (35.8%) |
| Female | 10 (8.4%) | 11 (9.2%) | 63 (52.9%) | 35 (29.4%) | |
| Total | 27 (7.2%) | 34 (9.0%) | 188 (50.0%) | 127 (33.8%) | |
| Runny nose | Male | 49 (74.2%) | 13 (19.7%) | 2 (3.0%) | 2 (3.0%) |
| Female | 21 (63.6%) | 5 (15.1%) | 3 (9.1%) | 4 (12.1%) | |
| Total | 70 (70.7%) | 18 (18.2%) | 5 (5.0%) | 6 (6.1%) | |
| Cough | Male | 141 (68.8%) | 44 (21.5%) | 11 (5.4%) | 9 (4.4%) |
| Female | 74 (74.0%) | 12 (12.0%) | 7 (7.0%) | 7 (7.0%) | |
| Total | 215 (70.5%) | 56 (18.4%) | 18 (5.9%) | 16 (5.2%) | |
| Sore throat | Male | 168 (92.8%) | 9 (5.0%) | 2 (1.1%) | 2 (1.1%) |
| Female | 84 (86.6%) | 10 (10.3%) | 1 (1.0%) | 2 (2.1%) | |
| Total | 252 (90.6%) | 19 (6.8%) | 3 (1.1%) | 4 (1.4%) | |
| Shortness of breath | Male | 20 (17.5%) | 39 (34.2%) | 50 (43.9%) | 11 (9.6%) |
| Female | 14 (22.9%) | 29 (47.5%) | 12 (19.7%) | 6 (9.8%) | |
| Total | 34 (18.8%) | 68 (37.6%) | 62 (34.2%) | 17 (9.4%) | |
| Body ache | Male | 105 (55.3%) | 68 (35.8%) | 10 (5.3%) | 7 (3.7%) |
| Female | 38 (49.35%) | 28 (36.4%) | 7 (9.1%) | 4 (5.2%) | |
| Total | 143 (53.6%) | 96 (36.0%) | 17 (6.4%) | 11 (4.1%) | |
| Diarrhea | Male | 81 (88.0%) | 7 (7.6%) | 3 (3.3%) | 1 (1.1%) |
| Female | 28 (80.0%) | 4 (11.4%) | 3 (8.6%) | 0 (0.0%) | |
| Total | 109 (85.8%) | 11 (8.7%) | 6 (4.7%) | 1 (0.8%) | |
| Loss of taste | Male | 12 (6.0%) | 31 (15.4%) | 140 (69.6%) | 18 (9.0%) |
| Female | 8 (10.3%) | 23 (29.5%) | 39 (50.0%) | 8 (10.3%) | |
| Total | 20 (7.2%) | 54 (19.3%) | 179 (64.2%) | 26 (9.3%) | |
| Loss of smell | Male | 15 (9.2%) | 30 (18.6%) | 99 (61.5%) | 17 (10.6%) |
| Female | 5 (8.93%) | 21 (37.50%) | 23 (41.1%) | 7 (12.5%) | |
| Total | 20 (9.2%) | 51 (23.5%) | 122 (56.2%) | 24 (11.1%) | |
| Vomiting | Male | 28 (54.9%) | 21 (41.2%) | 2 (3.9%) | 0 (0.0%) |
| Female | 16 (51.6%) | 9 (29.0%) | 3 (9.7%) | 3 (9.7%) | |
| Total | 44 (53.7%) | 30 (36.6%) | 5 (6.1%) | 3 (3.7%) | |
| Headache | Male | 82 (71.9%) | 16 (14.0%) | 7 (6.1%) | 9 (7.9%) |
| Female | 40 (71.4%) | 6 (10.7%) | 7 (12.5%) | 3 (5.4%) | |
| Total | 122 (71.8%) | 22 (13.0%) | 14 (8.2%) | 12 (7.1%) | |
| Digestive problems | Male | 10 (27.8%) | 22 (61.1%) | 1 (2.8%) | 3 (8.3%) |
| Female | 10 (47.6%) | 6 (28.6%) | 2 (9.5%) | 2 (9.5%) | |
| Total | 20 (35.1%) | 28 (49.1%) | 4 (7.0%) | 5 (8.8%) | |
| Lack of appetite | Male | 28 (25.2%) | 73 (65.8%) | 5 (4.5%) | 5 (4.5%) |
| Female | 15 (25.4%) | 35 (59.3%) | 7 (11.9%) | 2 (3.4%) | |
| Total | 43 (25.3%) | 108 (63.5%) | 12 (7.1%) | 7 (4.1%) | |
| Rashes | Male | 23 (74.2%) | 7 (22.6%) | 0 (0.0%) | 1 (3.2%) |
| Female | 9 (81.8%) | 0 (0.0%) | 0 (0.0%) | 2 (18.2%) | |
| Total | 32 (76.2%) | 7 (16.7%) | 0 (0.0%) | 3 (7.1%) | |
| Blistering | Male | 5 (71.4%) | 1 (14.3%) | 0 (0.0%) | 1 (33.3%) |
| Female | 1 (33.3%) | 1 (33.3%) | 0 (0.0%) | 1 (33.3%) | |
| Total | 6 (60.0%) | 2 (20.0%) | 0 (0.0%) | 2 (20.0%) | |
| Confusion | Male | 24 (42.1%) | 14 (24.6%) | 4 (7.0%) | 15 (26.3%) |
| Female | 9 (36.0%) | 3 (12.0%) | 6 (24.0%) | 7 (28.0%) | |
| Total | 33 (40.2%) | 17 (20.7%) | 10 (12.2%) | 22 (26.8%) | |
| Loss of speech | Male | 17 (41.5%) | 12 (29.3%) | 4 (9.8%) | 8 (19.5%) |
| Female | 8 (50.0%) | 3 (18.7%) | 3 (18.7%) | 2 (12.5%) | |
| Total | 25 (43.9%) | 15 (26.3%) | 7 (12.3%) | 10 (17.5%) |
Values are expressed as frequency and % response of the final respondents). The percentage was calculated considering the samples in the individual groups.